Lund patient (n=142) | Other centres patient (n=227) | ||||
---|---|---|---|---|---|
Number | % | Number | % | Level of sign | |
*p<0.05; **p<0.01; ***p<0.001; †treatment without any other DMARD. | |||||
Number of treatment regimens | 153 | 100 | 251 | 100 | |
Female | 116 | 76 | 204 | 81 | |
Monotherapy† | 49 | 32 | 144 | 57 | *** |
Severely destroyed (expected HAQ reduction 20%) | 38 | 25 | 160 | 64 | *** |
Continuing systemic glucocorticoid treatment | 125 | 82 | 198 | 79 | |
Mean | SD | Mean | SD | ||
Disease duration (years) | 14.5 | 9.8 | 14.6 | 10.1 | |
Age (years) | 55.0 | 13.1 | 57.0 | 13.5 | |
Previous DMARDs | 4.1 | 1.9 | 4.3 | 2.2 | |
Continuing DMARDs | 0.90 | 0.7 | 0.5 | 0.6 | *** |
Continuing prednisolone dosage (mg/week) | 44.9 | 32.9 | 44.8 | 36.9 | |
DAS28 | 5.8 | 1.1 | 5.5 | 1.1 | * |
HAQ | 1.48 | 0.61 | 1.52 | 0.64 | |
ESR (mm/1st h) | 44.2 | 28.9 | 35.9 | 22.7 | ** |
CRP (mg/l) | 38.0 | 34.5 | 45.3 | 40.6 |